ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0296

Musculoskeletal Manifestations in Patients Diagnosed with Marfan Syndrome
Abstract Number: 1853

Mutated Nod2 Enhances Pathogenic Th17 Responses That Promote Experimental Blau Syndrome
Abstract Number: PP07

My Journey with Diffuse Scleroderma and Interstitial Lung Disease: A Pharmacist’s Perspective
Abstract Number: 1203

My Shoulder Hurts, What Should I Do? A Systematic Review and Bayesian Network Meta-analysis of Different Injectables in Glenohumeral Osteoarthritis
Abstract Number: 2199

Mycobacterial Infection and Renal and Bladder Malignancy in 2 IFNopathy Patients on High Doses of JAK Inhibitors
Abstract Number: 0295

Mycophenolate Mofetil in the Treatment of Patients with Isolated Cardiac Sarcoidosis
Abstract Number: 0688

Mycophenolate Mofetil Treatment in Limited Cutaneous Systemic Sclerosis Reduces the Risk of Vascular Complication Leading to Treatment Escalation: Emulation of a Target Trial Using Time-dependent Propensity Score-matching
Abstract Number: 0996

Myocarditis Following Pfizer-BioNTech BNT162b2 Vaccine: Epidemiology and Predisposition
Abstract Number: 2677

N-Acetylcysteine Blocks the Mechanistic Target of Rapamycin in Pro-Inflammatory Effector-Memory CD4 and CD8 T Cells Re-Expressing CD45RA in Patients with Active Systemic Lupus Erythematosus
Abstract Number: 2548

NADPH Oxidase in B Cells and Macrophages Protects Against Murine Lupus by Regulation of TLR7
Abstract Number: 2404

Nailfold Dermoscopy: A Valuable Tool for Differentiating Dermatomyositis from Systemic Lupus Erythematosus
Abstract Number: 1152

Nailfold Videocapillaroscopy Abnormalities in Different Autoimmune Inflammatory Myopathy Subsets
Abstract Number: 2446

Nailfold Videocapillaroscopy Findings in Patients with Limited Cutaneous versus Diffuse Cutaneous Systemic Sclerosis: The First Detailed Retrospective Study
Abstract Number: 2320

Nailfold Videocapillaroscopy Findings in Patients with Psoriatic Disease: Is There a Distinctive Psoriatic Pattern?
Abstract Number: 1233

Narrative Medicine Intervention for Mental Wellbeing in Juvenile Myositis and Juvenile Idiopathic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].